Other clinical outcomes
mild disability
Peak power output in the GXT increased in both groups, with higher change scores in SET. Validity criteria [All motor function measures also increased in both groups. For the 6MWT, improvements (43.9 m [MAT], 26.3 m [SET]) exceeded measurement error on group-level (≥11.1 m) and in the MAT also substantially exceeded minimal important change values for patients with mild disability (≥26.9 m) [
Descriptive data on clinical outcomes at admission, discharge, and change scores (TTTT-7.8 (6.5)-6.5 (5.2), n = 91.7 (8.5)-17.6–0.0-15.5–0.0-9.8–14.6-7.6 (5.8)-5.4 (5.3), n = 93.4 (4.3)-20.0–3.3-11.6–3.1-2.0–9.6TTT12.2 (60.2)36.2 (136.3), n = 1022.6 (130. 9)-108–119-97–364-154–3328.2 (79.7)10.6 (50.7), n = 1025.6 (56.2)-62–240-26–148-19–167TTT56.9 (10.7)53.0 (12.5), n = 10-3.9 (7.5)37–7138–74-18–353.0 (10.0)53.7 (11.3), n = 100.8 (11.4)28–6536–70-20–22TTT49.7 (9.1)52.9 (10.6), n = 101.2 (5.8)30–6236–67-10–949.2 (9.3)52.0 (8.8), n = 103.6 (6.1)35–6338–69-5–13TTT106.8 (37.1)101.7 (32.8), n = 92.2 (6.7)55–17565–165-10–10110.5 (42.7)130.7 (51.6), n = 714.3 (16.1)55–22595–2450–40TTT499.0 (90.1)544.8 (101.9), n = 943.9 (30.0)366–631399–700-25–77511.5 (89.6)537.1 (87.0), n = 926.3 (32.8)315–648365–660-14–81TTT5.20 (0.99)5.01 (0.79), n = 9-0.10 (0.40)4.05–7.103.95–6.5-0.61–0.654.98 (0.98)4.80 (0.55), n = 9-0.30 (0.61)3.90–7.054.35–6.10-1.10–0.50TTT8.19 (2.42)7.55 (2.21), n = 9-0.51 (1.12)4.95–11.374.91–10.72-2.45–1.527.48 (1.80)6.58 (1.33), n = 9-0.92 (1.07)5.52–11.624.90–8.85-2.77–0.43TTT23.0 (18.0–26.0)24.0 (19.0–26.5), n = 92.0 (-1.5–4.5)14–2814–30-4–624.0 (23.0–27.0)25.0 (23.0–28.0), n = 92.0 (0.0–2.0)12–2815–29-1–3TTT70.5 (21.3)67.8 (19.4), n = 100.2 (7.2)24.1–99.133.4–97.2-12.5–10.375.8 (14.9)72.1 (13.2), n = 8-2.6 (6.8)55.0–95.657.5–96.3-16.4–5.6All outcomes had n = 11 at T